BDNF and neurodegenerative disease: As reduced concentrations of BDNF have been observed in many psychiatric and neurodegenerative diseases in both animal models and human patients, as reviewed extensively in [136,137,138,139,140], chronically enhancing BDNF signaling via DREADDs might offer some interesting prospects towards possible therapeutic applications of the chemogenetic platform.